
Septerna Inc (SEPN) Stock Forecast & Price Target
Septerna Inc (SEPN) Analyst Ratings
Bulls say
Septerna is poised for success due to its strong pipeline in three highly lucrative therapeutic areas, backed by a proven Native Complex Platform. Their lead candidate, SEP-631, has the potential to become a best-in-class treatment for mast cell-driven diseases, while their TSHR NAM candidate and GLP-1R/GIPR/GCGR agonist candidate bring further diversity and potential revenue streams. With conservative assumptions applied, our DCF-based valuation yields a price objective of $40 per share, indicating a strong upside potential for investors. However, risks to achieving this price target include potential delays in development, setbacks in clinical trials, and partnership risks.
Bears say
Septerna is facing significant challenges with their pipeline, as their Phase 2 CSU trial with MRGPRX2 NAM, SEP-631, was jeopardized by competitor data, causing them to re-evaluate their plans. Furthermore, their Ph 2 AD study with EVO756 is expected to miss in 3Q26 due to a presumed lack of efficacy. While there is potential for SEP-479 to achieve success in the rare disease market, there are also significant risks that could impact the company's development and commercialization timelines. With a conservative financial outlook and potential dilution risk, Septerna's stock could face challenges in the coming years.
This aggregate rating is based on analysts' research of Septerna Inc and is not a guaranteed prediction by Public.com or investment advice.
Septerna Inc (SEPN) Analyst Forecast & Price Prediction
Start investing in Septerna Inc (SEPN)
Order type
Buy in
Order amount
Est. shares
0 shares